Emergent BioSolutions to Release Third Quarter 2024 Financial Results and Conduct Conference Call on November 6, 2024
Emergent BioSolutions (NYSE: EBS) has scheduled its third quarter 2024 financial results conference call for November 6, 2024, at 5:00 pm eastern time. The call will cover Q3 financial performance, recent business developments, and the company's financial outlook for full year 2024. Participants can join via webcast or telephone, with dial-in numbers provided for both U.S./New York (+1-646-968-2525) and U.S. & Canada toll-free (+1-888-596-4144). A replay will be available on the company's Investors webpage.
Emergent BioSolutions (NYSE: EBS) ha programmato la sua conference call per i risultati finanziari del terzo trimestre 2024 per il 6 novembre 2024, alle 17:00 ora orientale. Durante la chiamata si discuterà delle performance finanziarie del Q3, degli sviluppi aziendali recenti e delle previsioni finanziarie della compagnia per l'intero anno 2024. I partecipanti possono unirsi tramite webcast o telefono, con numeri di accesso forniti sia per gli Stati Uniti/New York (+1-646-968-2525) che per il numero verde degli Stati Uniti e Canada (+1-888-596-4144). Una registrazione sarà disponibile sulla pagina Investitori della compagnia.
Emergent BioSolutions (NYSE: EBS) ha programado su conferencia telefónica sobre los resultados financieros del tercer trimestre de 2024 para el 6 de noviembre de 2024, a las 5:00 p.m. hora del este. La llamada cubrirá el desempeño financiero del Q3, los desarrollos comerciales recientes y las perspectivas financieras de la compañía para todo el año 2024. Los participantes pueden unirse a través de webcast o teléfono, con números de acceso proporcionados tanto para EE.UU./Nueva York (+1-646-968-2525) como para el número gratuito de EE.UU. y Canadá (+1-888-596-4144). Se ofrecerá una repetición en la página web de Inversores de la compañía.
Emergent BioSolutions (NYSE: EBS)은 2024년 11월 6일 동부 표준시 기준 오후 5시에 2024년도 3분기 재무 결과에 대한 컨퍼런스 콜을 진행합니다. 이번 콜에서는 3분기 재무 성과, 최근 사업 개발 및 2024년 전년 대비 재무 전망에 대해 논의할 예정입니다. 참가자는 웹캐스트 또는 전화를 통해 참여할 수 있으며, 미국/뉴욕(+1-646-968-2525) 및 미국 및 캐나다 무료전화(+1-888-596-4144)의 다이얼인 번호가 제공됩니다. 회사의 투자자 웹 페이지에서 재생할 수 있는 녹화본이 제공됩니다.
Emergent BioSolutions (NYSE: EBS) a programmé sa conférence téléphonique concernant les résultats financiers du troisième trimestre 2024 pour le 6 novembre 2024, à 17h00 heure de l'Est. L'appel portera sur la performance financière du T3, les récents développements commerciaux et les perspectives financières de l'entreprise pour l'année complète 2024. Les participants peuvent se joindre par webinaire ou par téléphone, avec des numéros d'appel fournis pour les États-Unis/New York (+1-646-968-2525) et un numéro sans frais pour les États-Unis et le Canada (+1-888-596-4144). Un enregistrement sera disponible sur la page Investisseurs de l'entreprise.
Emergent BioSolutions (NYSE: EBS) hat seine Telefonkonferenz zu den Finanzergebnissen des dritten Quartals 2024 für den 6. November 2024 um 17:00 Uhr Eastern Time angesetzt. In der Konferenz werden die Finanzleistung für Q3, aktuelle Geschäftsentwicklungen und der finanzielle Ausblick des Unternehmens für das gesamte Jahr 2024 behandelt. Teilnehmer können sich per Webcast oder Telefon verbinden, wobei Zugangsnummern sowohl für die USA/New York (+1-646-968-2525) als auch für die gebührenfreie Nummer in den USA und Kanada (+1-888-596-4144) bereitgestellt werden. Eine Wiederholung wird auf der Investorenwebseite des Unternehmens verfügbar sein.
- None.
- None.
GAITHERSBURG, Md., Oct. 23, 2024 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) will host a conference call on Wednesday, November 6, 2024, at 5:00 pm eastern time to discuss the financial results for the third quarter of 2024, recent business developments, and financial outlook for full year 2024.
Webcast & Conference Call Information
Participants can access the conference call live via webcast. To join via telephone, please use the following dial-in details:
- U.S. / New York: +1-646-968-2525
- U.S. & Canada (Toll Free): +1-888-596-4144
- Conference ID: 5259189
A replay of the call can be accessed from the Investors page of Emergent’s website.
About Emergent BioSolutions
At Emergent, our mission is to protect and enhance life. For 25 years, we’ve been at work defending people from things we hope will never happen—so we are prepared just in case they ever do. We provide solutions for complex and urgent public health threats through a portfolio of vaccines and therapeutics that we develop and manufacture for governments and consumers. We also offer a range of integrated contract development and manufacturing services for pharmaceutical and biotechnology customers. To learn more about how we plan to protect or enhance 1 billion lives by 2030, visit our website and follow us on LinkedIn, X, Instagram, Apple Podcasts and Spotify.
Investor Contact:
Richard S. Lindahl
Executive Vice President, CFO
lindahlr@ebsi.com
Media Contact:
Assal Hellmer
Vice President, Communications
mediarelations@ebsi.com
FAQ
When will Emergent BioSolutions (EBS) release Q3 2024 earnings?
How can investors join Emergent BioSolutions (EBS) Q3 2024 earnings call?
Will Emergent BioSolutions (EBS) provide 2024 financial guidance during Q3 earnings?
